It is not surprising that the addition of ruxolitinib to UCB-Tregs did not add to their existing benefit of controlling systemic renal disease manifestations, as measured by urine albumin/creatinine ratio as well as anti-dsDNA IgG Ab. This evidence concerns the gene ALB and kidney disorder.